TMEM97 and early-onset autosomal dominant Alzheimer disease: σ2-R antagonists have also shown promising results in different mouse models of Alzheimer’s disease, traumatic brain injury, and alcohol abuse by counteracting the impaired synaptic function associated with the Aβ1-42 oligomer [149].